Tesamorelin before & after.

Tesamorelin results after six months

Deep abdominal fat fell by 15.2% in one large tesamorelin trial and 10.9% in another after 26 weeks. Both trials enrolled adults with HIV and excess abdominal fat. The changes were measured by CT, so they describe visceral fat around the organs—not pounds lost or a reduction in whole-body fat percentage. [1] [2]

First pivotal trial: 412 adults randomized; original clinical formulation administered daily. Published descriptive averages. The comparison does not predict an individual result. [1]

The second trial reproduced the direction of benefit but with a smaller average reduction. That variation matters: there is no single percentage every course delivers. Differences between trial participants and study results are part of the evidence. [2]

Results timeline: 13, 26 and 52 weeks

Thirteen weeks is an observed assessment point, not the first day the drug starts having an effect. The studies measured changes at scheduled visits; they do not supply a reliable day-by-day appearance timetable.

A visible four-week transformation cannot be promised from these results. Photographs can change with lighting, posture, abdominal tension and other changes during treatment. The trial outcomes above are measured fat changes, not a collection of selected transformation photographs.

Similarly, a 52-week value is not evidence that every additional month produces the same amount of loss. The tesamorelin dosage and duration guide explains the actual studied schedules and the current approved formulations.

Waist size and belly appearance

A smaller waist can accompany a similar body weight. Tesamorelin is described as weight neutral in its prescribing information. Fat distribution and body composition can change without a large loss on the scale. [5]

Belly-appearance ratings also improved in the clinical trials. That is a useful result, but a rating does not specify a clothing-size change or guarantee visible abdominal muscles. The fat beneath the skin did not significantly decrease in the second pivotal trial, which helps explain why appearance can change less than the visceral-fat scan. [2]

For a clearer distinction between the two fat compartments, see deep abdominal fat and subcutaneous fat.

Response varies—and some participants did not respond

In a pooled analysis, 69% of eligible tesamorelin completers achieved at least an 8% reduction in visceral fat by week 26. The corresponding figure was 33% with placebo. The threshold was defined in advance; the subsequent analysis compared responders and nonresponders. [6]

About one-third of that treated analysis group did not meet the 8% threshold. The same paper found that IGF-1 rose in responders and nonresponders, so a hormone increase alone does not prove that abdominal fat is falling. [6]

This also separates two questions: whether tesamorelin changes a blood marker and whether it produces the body-composition result being sought. The answer to one does not automatically answer the other.

Results in adults without HIV

A smaller trial followed 60 adults with abdominal obesity and reduced growth hormone secretion for 12 months. It found less visceral fat, a smaller waist and more lean mass with tesamorelin than with placebo. These were selected participants with obesity, not lean gym users. [7]

Body weight did not show a significant treatment effect, and abdominal subcutaneous fat did not significantly change. The study supports a shift in body composition, not major weight loss. Lean mass includes water and other fat-free tissue, so the 1.0 kg increase is not a direct measure of new muscle. [7]

Liver-fat changes after six and twelve months

A six-month trial in 50 adults with HIV found a median liver-fat change of −2.0 percentage points with tesamorelin, compared with +0.9 points with placebo. Liver fat was assessed by magnetic resonance spectroscopy, alongside CT measurements of visceral fat. [8]

Separate trial: 61 adults with HIV and fatty liver. The percentages above describe participants reaching the imaging threshold, not the amount of fat each person lost. [9]

In that one-year study, the estimated liver-fat treatment difference was 4.1 percentage points, or a 37% relative reduction versus placebo. Those figures describe the same comparison on different scales. They do not mean a 37-point drop in liver fat. [9]

These changes are meaningful scan findings. They are not proof of a fatty-liver cure or reversal of established cirrhosis, and the studies do not establish identical results outside HIV.

Deep abdominal fat can return after stopping

A successful course does not establish permanent fat removal. The withdrawal study directly tested what happened after stopping, making the rebound finding more informative than a single end-of-treatment photograph.

The evidence does not establish that a short break, a maintenance supplement or a repeated bodybuilding cycle prevents that return. Treatment duration and continuation need to follow the specific clinical use and response, rather than an assumption that the first course has permanently changed fat storage. [10]

Visible change and tolerability are separate outcomes

A smaller waist does not establish that treatment is safe for a particular person. Tesamorelin can raise IGF-1, affect glucose control and cause fluid retention or injection-site reactions. Fluid changes can also complicate the interpretation of body weight and lean mass. [5]

Use the side-effects article for the actual symptoms and monitoring issues. For product specifications, the tesamorelin buying page separates available formats; the clinical studies do not establish that every research-labelled product has the same exposure, purity or effect as the formulations tested.